AWK and Essential Utilities Clear Federal Antitrust Review, State Approvals Remain Key Hurdle

What happened

American Water and Essential Utilities announced that the Hart-Scott-Rodino waiting period for their proposed merger has expired, removing the federal antitrust review obstacle. This development confirms the transaction is not subject to further scrutiny by the U.S. Department of Justice or Federal Trade Commission. However, the merger still requires approval from state public utility commissions in seven states, which the DeepValue report identifies as the primary source of uncertainty. The report had noted that Pennsylvania has already moved to a litigated posture, and any conditions deemed 'burdensome' could undermine the deal's economics. The HSR clearance slightly de-risks the timeline but does not address the financial concerns around elevated leverage and negative free cash flow.

Implication

The expiration of the HSR waiting period eliminates a federal antitrust risk, but the merger's value still hinges on state commission approvals without burdensome conditions. The DeepValue report maintains a WAIT rating, emphasizing that AWK's high leverage (5.7x net debt/EBITDA) and negative free cash flow limit downside protection if regulatory conditions are unfavorable. Near-term catalysts include procedural schedules in Pennsylvania and other key states, with an observable checkpoint by June 2026 and a potential add point by September 2026 if clean approvals emerge. Investors should monitor any changes to the equity funding plan, as pulled-forward equity issuance would signal deteriorating per-share economics. Overall, the news is a small step forward but insufficient to alter the investment thesis at this time.

Thesis delta

The removal of federal antitrust review slightly increases the probability of deal completion on schedule, but the core thesis remains unchanged because state-level approvals are the primary source of regulatory risk. The WAIT rating stays intact as the market still prices an optimistic scenario relative to the company's financial leverage and regulatory exposure. No upward revision to the investment view is warranted until there is evidence of clean state approvals without burdensome conditions.